Riskpilot← Back to searchSign inGet full accessAlltomab Sverige AB
ABActiveOrg 5591096937Bäverns Gränd 15 BAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20170 employees
Revenue 2025
SEK 8K
EBITDA margin
80.1%
+485% vs 2024
Equity ratio
96.5%
Financial strength
Net profit 2025
SEK 4K
+579% vs 2024
| Revenue | SEK 8K | — |
| EBITDA | SEK 6K | +485% |
| Net profit | SEK 4K | +579% |
| Total assets | SEK 55K | -88% |
| Equity | SEK 54K | +9% |
| Employees | 0 | — |
Legal name
Alltomab Sverige AB
Org number
5591096937
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
24 april 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall tillhandahålla aktiebolag av standardtyp och vara behjälplig med sådana aktiebolagsärenden som fordrar registrering, medverka vid bildande av bolag, upprätta aktieägar- och handelsbolagsavtal samt utöva accosiationsrättslig konsultverksamhet, samt därmed förenlig verksamhet. Bolaget skall bedriva handel, äga och förvalta fast och lös egendom såsom värdepapper.
Address
Bäverns Gränd 15 B
Email
info@bradosti.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 157 | 306 | 210 | 0 | 8 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 129 | 287 | 179 | −2 | 6 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 129 | 287 | 179 | −2 | 6 |
| Net financials | — | 0 | 2 | 1 | −1 |
| Profit before tax | 130 | 287 | 181 | −1 | 5 |
| Tax | −27 | −59 | −37 | — | −1 |
| Net profit | 103 | 228 | 144 | −1 | 4 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 235 | 543 | 553 | 446 | 55 |
| Equity | 153 | 278 | 194 | 49 | 54 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 82 | 265 | 359 | 397 | 2 |
| Total debt | 82 | 265 | 359 | 397 | 2 |
EBITDA margin
80.1%
This company
15.8%
Market median
+407% vs market
20212025
Equity ratio
96.5%
This company
38.2%
Market median
+153% vs market
20212025
Return on equity
8.3%
This company
18.4%
Market median
-55% vs market
20212025
Net profit margin
59.2%
This company
8.1%
Market median
+631% vs market
20212025
Asset turnover
0.14×
This company
1.12×
Market median
-88% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Board of Directors | 2022 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Alltomab Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jinan Al Shakarchi | Board of Directors | 0 companies |
| Alsha Mohammed Al Shakarchi | Deputy Board Member | 0 companies |
| Zerow Tamar Khan Bradosti | Board of Directors | 0 companies |
| Rozhana Shad Hakim | Deputy Board Member | 0 companies |